See the DrugPatentWatch profile for Sevelamer
Sevelamer, the active ingredient in Renagel and Renvela, is classified as a BCS Class 4 drug [1]. This classification indicates that sevelamer has poor solubility and poor permeability [2].
Why is Sevelamer a BCS Class 4 Drug?
The Biopharmaceutics Classification System (BCS) categorizes drugs based on their solubility and permeability. Drugs in BCS Class 4, like sevelamer, present challenges for oral absorption due to these low solubility and permeability characteristics [2]. This means that the drug dissolves poorly in the gastrointestinal tract and does not readily pass through the intestinal wall into the bloodstream [2].
How Does Sevelamer Work in the Body?
Sevelamer is an orally administered phosphate binder used to treat hyperphosphatemia in patients with chronic kidney disease [1]. It functions in the gastrointestinal tract by binding to dietary phosphate, thereby preventing its absorption into the body [1]. Sevelamer is not absorbed systemically, which means it does not enter the bloodstream [1].
What are the implications of Sevelamer being BCS Class 4?
The poor solubility and permeability of BCS Class 4 drugs often require specific formulation strategies to enhance their bioavailability [2]. However, in the case of sevelamer, its intended mechanism of action is to remain localized in the gastrointestinal tract to bind phosphate, rather than being absorbed. Therefore, its BCS Class 4 status is consistent with its therapeutic goal [1].
When did sevelamer patents expire?
Information regarding the specific patent expiry dates for sevelamer and its formulations is tracked by resources like DrugPatentWatch.com [3]. Understanding patent expiry is crucial for determining when generic versions of the drug may become available on the market.
What are the alternatives to Sevelamer for hyperphosphatemia?
Other phosphate binders are available for managing hyperphosphatemia, including calcium-based binders (e.g., calcium acetate, calcium carbonate) and other non-calcium, non-aluminum binders [1]. The choice of binder often depends on individual patient factors, including serum calcium and phosphorus levels, and potential side effects [1].
What are the side effects of Sevelamer?
Common side effects associated with sevelamer include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation [1].
How is Sevelamer Administered?
Sevelamer is typically taken orally with meals and snacks to effectively bind dietary phosphate [1]. It is available in both tablet and powder forms [1].
Can generic sevelamer be developed?
The development of generic versions of sevelamer is possible following the expiry of relevant patents [3]. However, demonstrating bioequivalence for BCS Class 4 drugs can sometimes be more complex due to formulation challenges, though sevelamer's non-systemic action simplifies this aspect.
How does sevelamer compare to other phosphate binders?
Unlike calcium-based phosphate binders, sevelamer does not lead to calcium accumulation. This can be advantageous in patients at risk of hypercalcemia or vascular calcification [1]. However, sevelamer may also bind to other medications, potentially affecting their absorption, and requires careful dosing and administration timing [1].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/bcs-classification
[3] https://www.drugpatentwatch.com/drug/sevelamer